See more : Schaeffler AG (SHA.DE) Income Statement Analysis – Financial Results
Complete financial analysis of UroGen Pharma Ltd. (URGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of UroGen Pharma Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SunWay Biotech Co., LTD. (1271.TWO) Income Statement Analysis – Financial Results
- DFI Retail Group Holdings Limited (D01.SI) Income Statement Analysis – Financial Results
- DATAGROUP SE (D6H.DE) Income Statement Analysis – Financial Results
- FDM Group (Holdings) plc (FDDMF) Income Statement Analysis – Financial Results
- Amifa Co.,Ltd. (7800.T) Income Statement Analysis – Financial Results
UroGen Pharma Ltd. (URGN)
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 82.71M | 64.36M | 48.04M | 11.80M | 18.00K | 1.13M | 8.16M | 17.53M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 9.36M | 7.65M | 5.16M | 1.01M | 0.00 | 1.80M | 600.00K | 28.00K | 113.00K | 0.00 | 0.00 |
| Gross Profit | 73.35M | 56.70M | 42.89M | 10.79M | 18.00K | -675.00K | 7.56M | 17.50M | -113.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 88.68% | 88.11% | 89.27% | 91.45% | 100.00% | -59.84% | 92.65% | 99.84% | 0.00% | 0.00% | 0.00% |
| Research & Development | 45.61M | 52.91M | 47.64M | 47.31M | 49.30M | 36.93M | 18.70M | 10.29M | 10.52M | 4.01M | 2.33M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 60.20M | 39.57M | 8.81M | 6.42M | 1.90M | 890.00K | 1.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 93.27M | 82.84M | 87.54M | 90.22M | 60.20M | 39.57M | 8.81M | 6.42M | 1.90M | 890.00K | 1.06M |
| Other Expenses | 0.00 | 72.00K | 0.00 | 0.00 | -284.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 138.89M | 135.74M | 135.18M | 137.53M | 109.50M | 76.51M | 27.51M | 16.70M | 12.41M | 4.36M | 3.39M |
| Cost & Expenses | 148.25M | 143.40M | 140.33M | 138.54M | 109.50M | 78.31M | 28.11M | 16.73M | 12.41M | 4.36M | 3.39M |
| Interest Income | 2.64M | 1.01M | 212.00K | 1.63M | 4.62M | 1.87M | 0.00 | 1.00K | 0.00 | 120.00K | 83.00K |
| Interest Expense | 14.72M | 8.44M | 17.44M | 357.00K | 284.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.71M | 1.82M | 1.77M | 2.04M | 1.32M | 417.00K | 207.00K | 213.00K | 113.00K | 30.00K | 18.00K |
| EBITDA | -63.83M | -78.03M | -90.15M | -122.71M | -108.15M | -77.18M | -19.74M | 1.01M | -12.30M | -4.34M | -3.37M |
| EBITDA Ratio | -77.17% | -121.25% | -156.12% | -1,074.15% | -600,855.56% | -6,842.20% | -244.55% | 5.77% | 0.00% | 0.00% | 0.00% |
| Operating Income | -65.54M | -79.04M | -92.29M | -126.74M | -109.48M | -77.18M | -19.95M | 798.00K | -12.41M | -4.37M | -3.39M |
| Operating Income Ratio | -79.23% | -122.82% | -192.11% | -1,074.15% | -608,211.11% | -6,842.20% | -244.55% | 4.55% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -32.79M | -28.99M | -17.08M | 1.63M | 4.33M | 1.65M | -31.00K | -2.74M | -279.00K | -107.00K | 83.00K |
| Income Before Tax | -98.32M | -108.03M | -109.37M | -125.11M | -105.15M | -75.53M | -19.98M | -1.94M | -12.69M | -4.48M | -3.31M |
| Income Before Tax Ratio | -118.87% | -167.86% | -227.66% | -1,060.34% | -584,144.44% | -6,696.10% | -244.93% | -11.07% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.92M | 1.14M | 1.45M | 3.37M | -4.62M | 125.00K | 19.00K | 0.00 | 0.00 | 81.00K | 0.00 |
| Net Income | -102.24M | -109.16M | -110.82M | -128.48M | -100.53M | -75.66M | -20.00M | -1.94M | -12.69M | -4.56M | -3.31M |
| Net Income Ratio | -123.61% | -169.62% | -230.67% | -1,088.94% | -558,500.00% | -6,707.18% | -245.16% | -11.07% | 0.00% | 0.00% | 0.00% |
| EPS | -3.55 | -4.79 | -4.96 | -5.90 | -4.90 | -4.80 | -2.06 | -0.16 | -5.51 | -1.98 | -1.56 |
| EPS Diluted | -3.55 | -4.79 | -4.96 | -5.90 | -4.90 | -4.80 | -2.06 | -0.16 | -5.51 | -1.98 | -1.56 |
| Weighted Avg Shares Out | 28.83M | 22.81M | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 11.97M | 2.30M | 2.30M | 2.12M |
| Weighted Avg Shares Out (Dil) | 28.83M | 22.81M | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 11.97M | 2.30M | 2.30M | 2.12M |
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 35 new employees in connection with...
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights results from a long-term follow-up study with JELMYTO (mitomycin) for pyelocalyceal solution, which is FDA...
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the presentation of the Phase 3 ENVISION trial's efficacy and safety results at the Society...
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade
The mean of analysts' price targets for Urogen Pharma (URGN) points to a 209.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on UGN-102 (mitomycin) for intravesical solution, JELMYTO (mitomycin) for pyelocalyceal solution, and...
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights results from a long-term follow-up study with JELMYTO (mitomycin) for pyelocalyceal solution, which is FDA...
UroGen Pharma: Choice Based On Near Term High Value PDUFA
Urogen's UGN-102 for bladder cancer presents a $5 billion market opportunity, prompting a continued "Strong Buy" rating despite past misjudgments. FDA approval by 06/2025 is crucial, with UGN-102 potentially being the first FDA-approved treatment for low-grade intermediate-risk NMIBC. Urogen's financials...
UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN ) Q3 2024 Earnings Call Transcript November 6, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Liz Barrett - President and CEO Mark Schoenberg - CMO David Lin - CCO Chris Degnan...
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.68 per share a year ago.
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2024, and provided an overview of...
Source: https://incomestatements.info
Category: Stock Reports